These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2892770)

  • 1. The antidiabetic action of somatostatin-28 as assessed by the artificial endocrine pancreas: greater potency than somatostatin-14.
    Hadjidakis DI; Raptis SA; Raptis AE; Karaiskos C; Souvatzoglou A; Diamantopoulos EJ
    Horm Metab Res; 1987 Nov; 19(11):574-8. PubMed ID: 2892770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes.
    Osei K; O'Dorisio TM; Malarkey WB; Cataland S
    J Lab Clin Med; 1991 Jul; 118(1):56-64. PubMed ID: 2066644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics.
    Neuhaus C; Kerner W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of three days of blood glucose normalization by means of an "artificial endocrine pancreas" on the concentrations of growth hormone, glucagon, and cortisol in juvenile diabetics.
    Schock A; Schultz M; Kerner W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):93-6. PubMed ID: 395097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.
    Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA
    Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between somatostatin-28 and somatostatin-14 with respect to their biological effects in healthy humans and acromegalics.
    Hadjidakis DJ; Raptis SA; Souvatzoglou A; Karaiskos C; Diamantopoulos EJ; Moulopoulos SD
    Clin Physiol Biochem; 1986; 4(6):372-83. PubMed ID: 2880690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidiabetic action of somatostatin after oral glucose loading: due to suppression of glucagon and growth hormone or of intestinal carbohydrate absorption?
    Bratusch-Marrain P; Vierhapper H; Grubeck-Loebenstein B; Waldhäusl W; Nowotny P
    Horm Metab Res; 1981 Jun; 13(6):305-9. PubMed ID: 6114914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
    Gerich JE; Lorenzi M; Bier DM; Tsalikian E; Schneider V; Karam JH; Forsham PH
    J Clin Invest; 1976 Apr; 57(4):875-84. PubMed ID: 820717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.
    Rios MS; Navascues I; Saban J; Ordoñez A; Sevilla F; Del Pozo E
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1071-4. PubMed ID: 2876005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
    Saccà L; Sherwin R; Hendler R; Felig P
    J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.
    Rizza RA; Cryer PE; Gerich JE
    J Clin Invest; 1979 Jul; 64(1):62-71. PubMed ID: 36413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pancreatic glucagon and C-peptide secretion during hyperinsulinemia in euglycemic glucose clamp with or without somatostatin infusion in normal man.
    Wu MS; Ho LT
    Horm Metab Res; 1987 Jun; 19(6):253-6. PubMed ID: 2887501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of somatostatin on established induced ketosis.
    Fallucca F; Barbetti F; Maldonato A; Spallone V; Giangrande L; Gambardella S
    Horm Metab Res; 1982 Oct; 14(10):512-5. PubMed ID: 6129185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
    Villaume C; Beck B; Kolopp M; Toussain P; Debry G
    Biomed Pharmacother; 1986; 40(2):61-4. PubMed ID: 2875745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissociated effects of somatostatin analogs on arginine-induced insulin, glucagon and growth hormone release in acromegalic patients.
    Wajchenberg BL; Cesar FP; Leme CE; Borghi VC; Souza VC; Souza IT; Neto DG; Germek OA; Coy DH; Comaru-Schally AM
    Horm Metab Res; 1983 Oct; 15(10):471-4. PubMed ID: 6139329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exogenous somatostatin raises plasma insulin levels in patients with insulin-dependent diabetes mellitus.
    Kollind M; Moberg E; Lins PE; Adamson U
    Horm Metab Res; 1990 Nov; 22(11):581-3. PubMed ID: 1980258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of acetylsalicylic acid on blood glucose, plasma FFA, glycerol, 3-hydroxybutyrate, alanine, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetics.
    Giugliano D; Luyckx AS; Lefebvre PJ
    Diabete Metab; 1980 Mar; 6(1):39-46. PubMed ID: 6989660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of exogenous growth hormone on insulin requirements during closed loop insulin delivery in insulin-dependent diabetes mellitus.
    Bright GM; Melton RW; Rogol AD; Clarke WL
    Horm Metab Res; 1984 Jun; 16(6):286-9. PubMed ID: 6389295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a long-acting somatostatin derivative SMS 201-995 (sandostatin) on glucose homeostasis in type I diabetes mellitus.
    Navascues I; Gil J; Pascau C; Senén D; del Pozo E; Serrano-Ríos M
    Horm Res; 1988; 29(2-3):92-4. PubMed ID: 2900205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.